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ABSTRACT
Introduction: Introduction of new antibiotics
enabling single-dose administration, such as
oritavancin may significantly impact site of
care decisions for patients with acute bacterial
skin and skin structure infections (ABSSSI). This
analysis compared the efficacy of single-dose
oritavancin with multiple-dose vancomycin in
patients categorized according to disease
severity via modified Eron classification and
management setting.
Methods: SOLO I and II were phase 3 studies
evaluating single-dose oritavancin versus
7–10 days of vancomycin for treatment of
ABSSSI. Patient characteristics were collected at
baseline and retrospectively analyzed. Study
protocols were amended, allowing outpatient
management at the discretion of investigators.
In this post hoc analysis, patients were
categorized according to a modified Eron
severity classification and management setting
(outpatient vs. inpatient) and the efficacy
compared.
Results: Overall, 1910 patients in the SOLO
trials were categorized into Class I (520, 26.5%),
II (790, 40.3%), and III (600, 30.6%). Of the 767
patients (40%) in the SOLO trials who were
managed entirely in the outpatient setting
40.3% were categorized as Class II and 30.6%
were Class III. Clinical efficacy was similar
between oritavancin and vancomycin
treatment groups, regardless of severity
classification and across inpatient and
outpatient settings. Class III patients had
lower response rates (oritavancin 73.3%,
vancomycin 76.6%) at early clinical evaluation
when compared to patients in Class I (82.6%) or
II (86.1%); however, clinical cure rates at the
post-therapy evaluation were similar for Class
III patients (oritavancin 79.8%, vancomycin
79.9%) when compared to Class I and II
patients (79.1–85.7%).
Conclusion: Single-dose oritavancin therapy
results in efficacy comparable to multiple-dose
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INTRODUCTION
Oritavancin is a lipoglycopeptide antibiotic
approved by the Food and Drug
Administration (FDA) and the European
Medicines Agency (EMA) for use as a
single-dose treatment of acute bacterial skin
and skin structure infections (ABSSSI).
Approvals were based on results from two
identical Phase 3 clinical trials (SOLO I and II;
ClinicalTrials.gov identifiers, NCT01252719
and NCT01252732, respectively) of a single
intravenous (IV) dose of oritavancin compared
to multiple-dose vancomycin administered IV
for 7–10 days [1, 2]. Both clinical trials
demonstrated that a single-dose of oritavancin
was non-inferior to multiple-day vancomycin
therapy. Since a full course of therapy is
delivered in a single IV dose, oritavancin has
the potential to shift the treatment of ABSSSI to
the outpatient setting without compromising
efficacy and without the need for laboratory
monitoring (as is required with vancomycin) or
an indwelling IV catheter [3]. This approach can
affect how ABSSSI is managed, by reducing or in
some cases eliminating costs and risks of
hospitalization.
Shifting the care of ABSSSI to the outpatient
setting requires appropriate patient selection
based on severity of illness and patient-specific
comorbidities that may impact treatment
outcomes or require a higher level of care.
Evidence-based treatment guidelines or
pathways of care are increasingly used to select
the most appropriate treatment, including site
of care decisions. Although skin and skin
structure infections are extremely common,
there is a lack of validated evidence-based
schemes for the classification of clinical
presentation, disease severity, impact of
comorbidities, and site of care. Several
classification systems and treatment
algorithms have been published in recent
years in attempts to identify which patients
should be treated as inpatients versus
outpatients, the route of antibiotic
administration, and antibiotic choice [4–9].
The Eron classification was developed by an
expert panel of clinicians and researchers to
categorize severity to guide initial site of care
decisions for patients with skin and soft tissue
infections [5]. In the Eron classification,
patients are grouped into four categories of
ascending severity according to signs and
symptoms of infection and comorbidities.
Class I patients have no signs or symptoms of
systemic toxicity, have no uncontrolled
comorbidities that may complicate treatment
and usually can be managed on an outpatient
basis. Class II patients are either systemically ill,
but any comorbidities they may have are stable,
or are systemically well but have one or more
comorbidities. Class III patients may appear
toxic, or they may appear nontoxic but have
unstable comorbidities that may interfere with
their response to therapy. Class III patients
usually require initial inpatient treatment but
many can be quickly discharged on outpatient
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parenteral antimicrobial therapy (OPAT) or oral
therapy. Class IV patients have sepsis syndrome
or serious life-threatening infections (e.g.,
necrotizing fasciitis) and should be admitted
for stabilization. The Eron classification has
since been adapted by the Clinical Resource
Efficiency Support Team (CREST) into the
‘Guidelines on the Management of Cellulitis
in Adults’ (CREST guidelines) which are used
widely in the UK [6].
In view of the potential for outpatient
management of a substantial number of
patients, a clinical algorithm derived from the
Eron classification was used for a post hoc
analysis to evaluate patients enrolled in the
SOLO trials. Clinical efficacy of the single-dose
of oritavancin was compared to multiple-dose
vancomycin based on the modified Eron
classification and setting of care.
METHODS
SOLO I and II were two identical, phase 3,
multi-center, randomized, double-blind studies
that compared the efficacy and safety of a single
1200 mg dose of IV oritavancin to vancomycin
1 g IV twice daily for 7–10 days in adults with
ABSSSI [1, 2]. Patients randomized to
oritavancin received placebo infusions twice
daily to maintain treatment blinding. The
SOLO I and SOLO II protocols were amended
during the trials to allow patients to be
managed in the outpatient setting at the
discretion of the investigator. The SOLO trials
study design was consistent with current
regulatory guidelines for eligibility criteria, end
points, assessment methods and non-inferiority
margins.
Eligible patients were at least 18 years of age
and had received a diagnosis of ABSSSI that was
suspected or proven to be caused by a
Gram-positive pathogen and that required at
least 7 days of IV therapy. The diagnosis of
ABSSSI required the presence of wound
infection (either traumatic or surgical in
origin), cellulitis, or a major cutaneous abscess,
with each lesion surrounded by erythema,
edema, or an area of induration of at least
75 cm2. Signs and symptoms of systemic
inflammation were also required. Patients were
not eligible to participate if they received
systemic or topical antibacterial therapy with
Gram-positive activity within the preceding
14 days unless the documented failure to
previous therapy was available. Patients were
excluded if they had suspected or confirmed
bacteremia, severe sepsis or refractory shock, or
any evolving, necrotizing infection (i.e.,
necrotizing fasciitis).
Clinical evaluations were performed at: (1)
early clinical evaluation (ECE) 48–72 h after the
initiation of the therapy; (2) the end of therapy
(EOT) from Day 7 to Day 10; (3) Day 10
evaluation; (4) post-therapy evaluation (PTE)
in 7–14 days after the EOT; (5) safety follow-up
at 60 days (?7 days; Fig. 1). The primary efficacy
endpoint was a composite outcome at ECE
comprised (1) cessation of spreading or
reduction in the size of the baseline lesion, (2)
absence of fever, and (3) no rescue antibiotic
medication. The key secondary endpoint was
investigator-assessed clinical cure at PTE. The
additional main secondary efficacy outcome
was lesion size decrease by C20% from
baseline at ECE.
An algorithm based on the Eron
classification was developed and applied to the
modified intent-to-treat (mITT) pool of SOLO
patients to classify each patient enrolled in the
pooled dataset from the SOLO trials. The
algorithm incorporated signs and symptoms of
systemic illness in addition to concomitant
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medical conditions which have been implicated
in poor therapeutic response (advanced age,
chronic liver or renal disease, diabetes, obesity,
chronic venous insufficiency) that were
recorded in the case reports for each patient
[6, 10]. Clinical variables included data
collected in the SOLO trials, inclusion/
exclusion criteria, and input from clinical
experts. The clinical criteria are described in
Table 1. Patients were classified into Class I–IV
based on the presence of comorbidities and
systemic symptoms of infection. Stratification
criteria and assignment of patients to a
modified Eron class were performed by expert
consensus within a panel of seven advisors.
Patients categorized as Class IV (bacteremia or
absolute neutrophil count less than 500
detected after enrollment) were excluded from
this analysis as they were not considered
appropriate for outpatient management.
Location of care in the outpatient or inpatient
setting and all follow-up visits were
documented in the case report form.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the SOLO trials.
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Statistical Analysis
Discrete variables were summarized as
frequencies and percentages. Continuous
variables were summarized as means with
standard deviations (SD). Efficacy outcomes of
oritavancin and vancomycin therapy according
to modified Eron classification and receipt of
treatment in the outpatient or inpatient setting
were presented as percentages, differences and
two-sided 95% confidence intervals (CI) and
compared using Chi-square testing between two
treatment groups. The alpha level of
significance was set to 0.05. All p values being
presented were two-sided. This was a post hoc
exploratory analysis that was not powered for
statistical inference. All analyses were
Fig. 1 SOLO study design (n = 1959, mITT population).
ECE early clinical evaluation (48–72 h from treatment
initiation), EMA European Medicines Agency, FDA Food
and Drug Administration, hrs hours, IV intravenous,
mITT modiﬁed intent-to-treat, PTE post-therapy
evaluation (7–14 days after the end of therapy), Q every
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conducted using SAS version 9.2 (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Of the 1959 mITT patients in the SOLO studies,
520 (26.5%), 790 (40.3%), and 600 (30.6%) were
categorized into Class I, II, and III, respectively
(Table 2). The 49 patients categorized into
Class IV were excluded from this analysis since
initial inpatient management would generally
be considered standard of care for patients with
bacteremia and/or neutropenia. A majority of
the patients in the SOLO trials had significant
comorbidities and/or systemic symptoms of
infection as 70.9% of patients were categorized
as Class II or III. Demographics and baseline
characteristics were different across Class I–III
(Table 3). Patients in Class I, had a lower
incidence of comorbidities (diabetes, renal
insufficiency or hepatic conditions), were
younger, and had lower body mass index and
smaller mean lesion size. Mean lesion size
increased with severity classification. In
comparison to Class I and II patients, a greater
percentage of Class III patients were diagnosed
with cellulitis. Of Class III patients, 55.5% met
systemic inflammatory response syndrome
(SIRS) criteria (presence of two or more
systemic signs of infection).
Table 1 Clinical criteria used to deﬁne modiﬁed Eron Classes I–IV
Eron class Clinical criteria
IV Bacteremia (positive blood culture); or
Absolute total neutrophils count\500
III Meeting SIRS criteria
CrCl\20 mL/min or on dialysis
ALT/AST[10-times ULN
Heart rate[90/min, breath rate[20/min, or systolic BP\90 mmHg; or
Cancer
II Age C75 years old
Glucose[11.1 mmol/L
Congestive heart failure at the randomization
30 mL/min\CrCl\60 mL/min
Hepatitis (excluding AST/ALT[10-times ULN)
Peripheral vascular disease
Diabetes mellitus
Fever (temperature[38.0 C); or
BMI C30 kg/m2
I For the patients who didn’t meet Classes II–IV
ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, BP blood pressure, CrCl creatinine clearance,
SIRS systemic inﬂammatory response syndrome, ULN upper limit of normal
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Table 2 Distribution of SOLO patients in modiﬁed Eron Classes I–III (mITT population, n = 1959)
Class I Class II Class III Total (Class I–III)
SOLO mITT (n = 1959) 520 (26.5%) 790 (40.3%) 600 (30.6%) 1910
Inpatients, n (%) 301 (57.9%) 431 (54.6%) 411 (68.5%)
ORI, n 144 224 203 571
VAN, n 157 207 208 572
Outpatients, n (%) 219 (42.1%) 359 (45.4%) 189 (31.5%) 767 (40.2%)
ORI, n 108 182 89 379
VAN, n 11 177 100 388
mITT modiﬁed intent-to-treat, ORI oritavancin, VAN vancomycin
Table 3 Demographics and baseline characteristics by classiﬁcation (mITT population)
Parameter Class I (N5 520) Class II (N5 790) Class III (N5 600)
Age, years (mean ± SD) 40.1 ± 13.6 47.8 ± 13.2 45.4 ± 14.6
Male 73.7% 61.5% 64.0%
White 55.8% 71.8% 61.7%
BMI, kg/m2 (mean ± SD) 24.0 ± 3.3 29.9 ± 8.4 28.2 ± 8.6
Disease condition
Cellulitis/Erysipelas 35.4% 39.2% 46.8%
Major cutaneous abscess 31.7% 30.3% 30.2%
Wound infection 32.9% 30.5% 23.0%
Lesion size, cm2 (mean ± SD) 325.7 ± 317.8 418.0 ± 471.1 466.7 ± 479.1
Days from infection onset to treatment start 4.3 ± 2.1 4.4 ± 2.9 4.4 ± 2.4
Meeting SIRS criteria 0.0% 0.0% 55.5%
Conﬁrmed MRSA 24.0% 17.8% 20.0%
Medical history
Diabetes mellitus 0.0% 20.0% 18.3%
Intravenous drug use 23.3% 38.7% 20.5%
Hepatitis/other hepatic condition 0.0% 37.6% 14.3%
Renal insufﬁciency 0.2% 1.6% 2.8%
SIRS was deﬁned as two or more of the following criteria: Temperature[38 C, pulse[90 bpm, respiratory rate[20
breaths per minute, white blood cell count[12,000/mm3, or\4000 or[10% bandemia
BMI body mass index, mITT modiﬁed intent-to-treat, MRSA methicillin-resistant Staphylococcus aureus, SD standard
deviation, SIRS systemic inﬂammatory response syndrome
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Overall 40% (n = 767) of all patients in the
SOLO trials were managed as outpatients. The
percentages of patients treated entirely at an
outpatient setting were 42.1%, 45.4%, and 31.5%
in Class I, II, and III patients, respectively
(Table 2). Of the patients who were enrolled in
the United States, 73% were managed in the
outpatient setting and of those, 71% were Class
II–III, which is similar to the overall study
population. The combined efficacy for both
drugs using the primary endpoint of clinical
response at ECE for outpatients versus inpatients
in Class I patients was 79% vs. 88.7%, Class II
patients 82.7% vs. 84.7%, and 73% vs. 75.9% in
Class III patients, respectively.
Within each Class (I–III), patients receiving
oritavancinexperiencedsimilar clinicalefficacyas
those receiving vancomycin for the primary
composite ECE outcome, lesion size reduction at
ECE, and clinical cure at PTE. Treatment
outcomes for oritavancin and vancomycin were
also similar within each class when patients were
analyzed by inpatient or outpatientmanagement
setting (Fig. 2). Response rates at ECE for patients
in Class III (75.0%) were lower than those
observed with patients in Class I (84.6%,
P\0.001) and Class II (83.8%, P\0.001).
However, at PTE the response rates did not differ
between Class III (79.1%) and Class I (82.3%,
P = 0.293) or Class II (81.1%, P = 0.542).
DISCUSSION
A clinical algorithm based on the Eron
classification system that stratifies patients
based on the presence of systemic symptoms
of infection and comorbidities associated with
poor outcomes was developed and applied to
ABSSSI patients pooled from two randomized
controlled clinical trials. In this post hoc
analysis of the SOLO trials, Class I and II
patients treated with a single-dose of
oritavancin or vancomycin twice daily
administered over 7–10 days had similar
Fig. 2 Primary and secondary endpoints by classiﬁcation
and treatment (mITT population). CI conﬁdence interval,
ECE early clinical evaluation (48–72 h from treatment
initiation), IPAT inpatient parenteral antibiotic therapy,
mITT modiﬁed intent-to-treat, OPAT outpatient
parenteral antibiotic therapy, ORI oritavancin, PTE
post-therapy evaluation (7–14 days after the end of
therapy), VAN vancomycin
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response rates if they were managed in the
inpatient or outpatient settings. Results of this
analysis suggest the majority of patients in Class
I and II can be safely managed in the outpatient
setting.
Class III patients in the SOLO trials had
numerically lower responses to both drugs at
ECE (oritavancin 73.3%, vancomycin 76.6%)
when compared to Class I–II patients
(82.6–86.1%), although rates were similar
between each drug and management settings.
The response rates of Class III patients at PTEwere
approximately80%(similar to rates inEronClass I
and II) in both vancomycin and oritavancin
groups regardless of site of care. This suggests
that Class III patientsmay have had a slower early
treatment response but still achieved investigator
defined clinical cure at rates similar to Class I–II
patients. Of note, a smaller overall percentage
(31.5%) of Class III patients was managed in the
outpatient setting. This likely represents a more
guarded approach to managing patients
presenting with unstable comorbidities or SIRS
criteria. A lower response rate in Class III patients
using an endpoint of 30-day mortality has also
been identified previously [9]. Patients presenting
with SIRS criteria require close monitoring and
management to ensure an adequate clinical
response. This management may occur as an
outpatient in an observation unit or as an
inpatient. Patients with a rapid clinical response
may be candidates for continuedmanagement in
the outpatient setting once stabilized.
One limitation to this analysis is that while
the Eron/CREST treatment guidelines provide
an approach to patient stratification, they have
not been rigorously validated by clinical studies.
The Eron classification has been criticized for
being ambiguous with respect to the patient
characteristics in the different severity
classifications as well as being difficult to
translate into real world treatment protocols
[7, 8]. However, the Eron classification
incorporates several important patient factors
and was shown in a retrospective analysis of
Premier database that Eron Classes I–IV
correlated with increasing Charlson
Comorbidity Index score, proportion of
inpatients, in-hospital mortality rate, length of
hospital stay, cost per patient and the use of
MRSA-active antibiotics [11].
CONCLUSIONS
The results demonstrate that single-dose
oritavancin is an effective alternative to
7–10 days of IV vancomycin for the treatment
of patients with ABSSSI within modified Eron
Classes I–III. Management in the inpatient or
outpatient setting was associated with
comparable efficacy. Tools such as the Eron
classification may be useful in the identification
of patients with ABSSSI that could be managed
in the outpatient setting, thereby avoiding
hospitalization.
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